The FDA approved an expansion of hospital eligibility for Humacyte's Symvess drug.
5 reports, 4 independent
Updated Aug 18
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 5
- Developments
- 2
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA approved an expansion of hospital eligibility for Humacyte's Symvess drug.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA expanded hospital eligibility for Humacyte's Symvess drug.1 source
Symvess is approved by FDA for vascular trauma and made available to DOD and VA.1 source
Keep exploring
The entities involved
- FDA
-
Humacyte (United States)
company in Morrisville, United States
Nothing else this week.
Related events
- The FDA recommended advancement for a new drug application submitted by a company.
- Symvess is seeking FDA approval for a product related to dialysis access.
- The FDA placed a clinical hold on the IND application for the company Aardvark.
- Biocon's subsidiary received FDA approval for a drug in the United States on August 18, 2026.
Coverage
Newest first; wire copies grouped- manilatimes.net
- yahoo.com
- GuruFocus.comHumacyte Inc (HUMA) Q2 2025 Earnings Call Highlights: Navigating Challenges and Celebrating ... Revenue: $0.3 million for Q2 2025; $0.8 million for the six months ended June 30, 2025. Symvess Sales:
- GlobeNewswireHumacyte Announces First Symvess™ Sale to Military Treatment Facility Sale follows recent Electronic Catalog (ECAT) listing approval by U.S. Defense Logistics Agency Symvess now available to U.S. Dep
- Unknown outlet